CBD and Its Metabolites Did Not Behave Identically in Cannabinoid Urine Screens
An experiment with six cannabinoid urine immunoassays found no cross-reactivity from parent CBD at the highest concentration tested, while certain hydroxylated CBD metabolites reacted in some assays at lower screening cutoffs. A statement about CBD alone therefore does not describe every related compound or test configuration.
Fortified urine, rather than a CBD dosing trial
Researchers added individual cannabinoid standards to verified drug-free human urine and tested six commercial homogeneous immunoassays on one analyzer platform. Initial concentrations ranged from 20 to 1,000 ng/mL, followed by additional work around selected decision points.
The assays were evaluated at a 50 ng/mL cutoff and a lower cutoff of 20 or 25 ng/mL, depending on the kit. Those cutoffs describe calibration against the intended THC-COOH target, not necessarily the actual concentration of a different compound producing the signal.
Cutoff and chemical identity changed the result
Parent CBD and 7-carboxy-CBD did not react at concentrations up to 1,000 ng/mL in the evaluated configurations. Some assays reacted to 6-hydroxy-CBD or 7-hydroxy-CBD at lower cutoffs, although these metabolites did not produce positive responses at the 50 ng/mL cutoff under the tested conditions.
Delta-8 THC metabolites and HHC carboxy metabolites also cross-reacted. Responses differed among compounds and kits. A positive cannabinoid screen consequently cannot identify the specific cannabinoid solely from its generic label.
Analytical possibility is not a clinical frequency estimate
The study shows what happened when known compounds were added to urine. It did not determine how often CBD users reach these concentrations, how frequently a particular product causes a positive screen, or the full excretion time course.
Likewise, no reaction at the highest tested concentration means none was observed within that experiment’s range. It is not proof of zero response under every possible condition.
Separate cross-reactivity from actual THC exposure
A product containing THC can lead to genuine THC-related exposure, which is a different explanation from another compound triggering an antibody-based assay. Resolving a particular result requires the exact kit, cutoff and appropriately specific confirmatory analysis.
These urine experiments measured analytical response, not psychoactive effect or driving ability. Neither a cross-reactive signal nor a confirmed urinary metabolite result independently establishes impairment at an earlier event.
Related: Interpreting THC concentration and impairment.
Primary research
The cross-reactivity of cannabinoid analogs (delta-8-THC, delta-10-THC and CBD), their metabolites and chiral carboxy HHC metabolites in urine of six commercially available homogeneous immunoassays. DOI: 10.1093/jat/bkad059.
